Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: A prospective series of nine patients

Clinical and Experimental Rheumatology

Volumn 27, Issue 3, 2009, Pages 416-421

  Matsumura, Ryutato ^a   Umemiya, Keiko ^a   Sugiyama, Takao ^b   Sueishi, Makoto ^b   Umibe, Tuyoshi ^c   Ichikawa, Kenji ^d   Yoshimura, Mitsuhiro ^e  

^a SAKURA NATIONAL HOSPITAL   (Japan)

^b National Hospital Organization   (Japan)

^c Department of Internal Medicine   (Japan)

^d HOKKAIDO MEDICAL CENTER   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION KANAZAWA MEDICAL CENTER   (Japan)

Author keywords

Infliximab; Lupus nephritis; Tumor necrosis factor

Indexed keywords

AZATHIOPRINE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DNA ANTIBODY; INFLIXIMAB; METHYLPREDNISOLONE; MIZORIBINE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; BRAIN STEM INFARCTION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENT BLOOD LEVEL; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG PULSE THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INFUSION REACTION; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; PYELONEPHRITIS; SIDE EFFECT; TREATMENT RESPONSE;

ADULT; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DNA; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINURIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67651149869     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. MAURY CP, TEPPO AM: Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum 1989; 32: 146-150 (Pubitemid 19056401)
2. DAVAS EM, TSIROGIANNI A, KAPPOU I et al.: Serum IL-6, TNFalpha, p55 srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus. Clin Rheumatol 1999; 18: 17-22.
3. TESAR V, MASEK Z, RYCHLIK I et al.: Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. Nephrol Dial Transplant 1998; 13: 1662-1667
4. ARINGER M, SMOLEN JS: Cytokine expression in lupus kidneys. Lupus 2005; 14: 13-18
5. BRENNAN DC, YUI MA, WUTHRICH RP et al.: Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. J Immunol 1989; 143: 3470-3475
6. EDWARDS CK, 3RD, ZHOU T, ZHANG J et al.: Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-alpha. J Immunol 1996; 157: 1758-1772
7. JACOB CO, MCDEVITT HO: Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature 1988; 331: 356-358
8. FAVALLI EG, SINIGAGLIA L, VARENNA M et al.: Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 2002; 11: 753-755
9. ALI Y, SHAH S: Infliximab-induced systemic lupus erythematosus. Ann Intern Med 2002; 137: 625-626
10. PRINCIPI M, DI LEO A, INGROSSO M et al.: Lupus nephritis improvement after anti-tumor necrosis factor alpha monoclonal antibody (infliximab) treatment for Crohn's disease: a case report. Immunopharmacol Immunotoxicol 2004; 26: 243-248
11. ARINGER M, GRANINGER WB, STEINER G et al.: Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004; 50: 3161-3169
12. HAYAT SJ, UPPAL SS, NARAYANAN NAMPOORY MR et al.: Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis. Clin Rheumatol 2007; 26: 973-975
13. BOMBARDIER C, GLADMAN DD, UROWITZ MB et al.: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640
14. WEENING JJ, D'AGATI VD, SCHWARTZ MM et al.: The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521-530 (Pubitemid 38130646)
15. ARINGER M, STEINER G, GRANINGER WB et al.: Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 274-279
16. DE BANDT M, SIBILIA J, LE LOET X et al.: Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005; 7: R545-51.
17. EDREES AF, MISRA SN, ABDOU NI: Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin Exp Rheumatol 2005; 23: 469-474
18. MARTINEZ-BORRA J, LOPEZ-LARREA C, GONZALEZ S et al.: High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol 2002; 97: 2350-2356
19. SABRY A, SHEASHAA H, EL-HUSSEINI A et al.: Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: its correlation with disease activity. Cytokine 2006; 35: 148-153
20. ARINGER M, SMOLEN JS: The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther 2008; 10: 202.
21. KASITANON N, PETRII M, HAAS M et al.: Mycophenolate mofetil as the primary treatment of membrous lupus nephritis with and without concurrent proliferative disease: a retrospective.study of 29 cases. Lupus 2008; 1: 40-45
22. KAPETANOVIC MC, LARSSON L, TRUEDSSON L et al.: Predictors of reactions during infliximab treatment in patients with arthritis. Arthritis Res Ther. 2006; 8: R131.
23. GONNET-GRACIA C, BARNETCHE T, RICHEZ C et al.: Antinuclear antibodies, anti-DNA and C4 complement evolution inrheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers. Clin Exp Rheumatol 2008; 26: 401-407
24. CAVAZZANA I, BOBBIO-PALLAVINCINI F, FRANCESCHINI F et al.: Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients. Clin Exp Rheumatol 2007; 25: 676-683